Citigroup’s NeuroOne Medical Technologies NMTC Stock Holding History

Citigroup’s Portfolio NMTC Stock Details NMTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-163	Closed	-$757	–	6080
2026 Q1	$757	Buy	+163	New	+$783	﹤0.01%	5502

Other funds holding NMTC

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Citigroup's NMTC Position: Q2 2026 in Review

Citigroup sold out of NeuroOne Medical Technologies (NMTC) in Q2 2026, closing a stake of 163 shares — an estimated $757 sold.

Citigroup first reported a position in NMTC in Q1 2026 and held it in 1 quarter. The position peaked at $757 in Q1 2026. 27 funds tracked by Wall St. Rank hold NMTC as of Q2 2026.

Citigroup reported no remaining NeuroOne Medical Technologies position as of Q2 2026 after selling out during the quarter.
Citigroup sold 163 NeuroOne Medical Technologies shares in Q2 2026, an estimated $757.
Citigroup first reported a position in NeuroOne Medical Technologies in Q1 2026 and held it in 1 quarter.
Citigroup's NeuroOne Medical Technologies position peaked at $757 in Q1 2026.
27 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.